Every 8-K that Outset Medical, Inc. (OM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OM filings page.
Outset Medical, Inc. (OM) reports that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities. The company states that his departure is not due to any dispute or disagreement with the company or its management.
Outset Medical, Inc. reported second quarter 2026 results, with total revenue of $31.6 million, up 1% from $31.4 million a year earlier and 14% sequentially. Product revenue was $21.9 million, while service and other revenue increased to $9.7 million, a 17% rise year over year. Recurring revenue from Tablo consumables and services was $22.1 million.
Gross profit was $13.3 million and gross margin expanded to 42.0% from 37.8%, with service and other gross margin rising to 32.6% from 6.9%. Operating expenses were $29.0 million, roughly flat year over year. Net loss was $18.0 million, or $0.97 per share. Total cash, cash equivalents, short-term investments and restricted cash were $151.0 million as of June 30, 2026. The company signed a three-year, $40 million agreement with HCA Healthcare to refresh its Tablo system fleet and reiterated 2026 revenue guidance of $125 million to $130 million, with expected non-GAAP gross margin in the low-40% to mid-40% range.
Outset Medical, Inc. entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, under which HCA will refresh its fleet of Tablo Hemodialysis Systems. HCA plans to purchase new Tablo systems from 2026 through the end of 2028 for an aggregate contract value of approximately $40 million, net of rebates and allowances.
The agreement is described as a committed capital purchase and includes a console and consumables purchase framework that can support potential future growth beyond HCA hospitals already using Tablo. Outset Medical is reiterating its previously issued 2026 guidance and expects to provide more detail on the 2026 financial impact of this amendment later in the year once it better understands the timing and ramp of implementation.
Outset Medical, Inc. reported the results of its Annual Meeting of Stockholders held on June 4, 2026 via virtual audio webcast. As of the April 9, 2026 record date, 18,529,233 shares of common stock were outstanding and entitled to vote, and 13,890,864 shares were represented at the meeting, establishing a quorum.
Stockholders elected Brent D. Lang and Karen Prange as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers. In addition, stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Outset Medical, Inc. reported a leadership change as Executive Vice President, R&D, Operations and Service, Marc Nash, has decided to depart the company. His role will end effective June 5, 2026, as he pursues other professional opportunities.
The company stated that Mr. Nash’s departure is not due to any dispute or disagreement with the company or its management, framing this as a voluntary transition rather than a conflict-driven exit.
Outset Medical, Inc. reported first-quarter 2026 revenue of $27.9 million, down 6% from $29.8 million a year earlier, as lower product revenue offset growth in services. Recurring Tablo consumables and service revenue was $22.5 million, roughly flat with the prior-year period.
Gross profit rose to $12.1 million and gross margin expanded to 43.4% from 37.2%, helped by record product gross margin of 52.4% and service and other gross margin of 25.5%. GAAP net loss narrowed to $19.0 million, or $1.03 per share, compared with a $25.8 million loss. On a non-GAAP basis, net loss was $15.4 million versus $22.8 million.
Operating expenses increased to $29.0 million from $27.5 million, reflecting higher general and administrative spending, including stock-based compensation and litigation charges. Total cash, including restricted cash, cash equivalents and investments, was about $160.5 million as of March 31, 2026. The company reiterated 2026 revenue guidance of $125–$130 million, a 5% to 9% increase over $119.5 million in 2025, and continues to target non-GAAP gross margin in the low to mid-40% range.
Outset Medical reported full-year 2025 revenue of $119.5 million, up 5% from 2024, with gross margin improving to 39.1% from 33.9%. Net loss narrowed to $81.7 million versus $128.0 million a year earlier as operating expenses fell significantly.
Recurring revenue from Tablo consumables and services grew 6% to $88.7 million, and total cash, including investments, reached $172.8 million at year-end. The company also received FDA clearance for its next-generation Tablo platform. For 2026, it guides revenue to $125–$130 million and expects non-GAAP gross margin in the low to mid-40% range.
Outset Medical, Inc. reported that the U.S. Food and Drug Administration has granted 510(k) clearance for its next-generation Tablo hemodialysis platform. This clearance allows the updated system to be marketed in the United States under its cleared indications.
The company stated that it expects to begin shipping the next-generation Tablo platform to customers in the second quarter of 2026. Outset highlighted that future performance and impact of the product, as well as the timing of enhancements and new features, remain subject to various risks and uncertainties described in its SEC filings.
Outset Medical, Inc. reported that it issued a press release with expected revenue for the fourth quarter and full year ended December 31, 2025, noting that this financial information is preliminary, unaudited and may change as closing and audit processes are completed. The company also furnished an updated investor presentation.
Board member Andrea Saia resigned effective January 9, 2026, and the company stated her departure was not due to any disagreement on operations, policies or practices. The Board appointed Karen Prange as a new independent director and Compensation Committee member, filling the vacancy as a class III director with a term running until the 2026 annual meeting. In connection with her appointment, Prange will receive an initial grant of 18,667 restricted stock units that vest quarterly over three years and an annual grant of 10,667 restricted stock units, subject to the company’s non‑employee director compensation policy.
Outset Medical (OM) furnished an 8-K stating it issued a press release and will hold its earnings call to announce financial results for the quarter ended September 30, 2025, along with revised 2025 revenue guidance.
The company notes the information is furnished under Item 2.02 and not deemed filed. The report includes forward‑looking statements and points readers to SEC filings for risk factors. Exhibit 99.1 contains the press release titled “Outset Medical Reports Third-Quarter Results.”